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Abstract
Studies on gastric microbiota find several bacterial families and species in the stomach 
using molecular-based techniques. When biopsies are cultured, there may be growth of 
bacteria, pure culture of Helicobacter pylori, or no growth. When looking at the histological 
sections of corresponding biopsies no bacteria may be seen, except curved rods (H. pylori) 
adherent to the gastric epithelial cells. In a number of biopsies, several different bacteria 
are cultured with or without H. pylori. The non–H. pylori bacteria cultured are like the 
normal oral flora and may be contamination of the samples during endoscopy. In his-
tological sections, these bacteria are seen above the mucin layer and not adherent to the 
epithelial cells confirming that it is contamination of the samples and can thus not be 
regarded as gastric microbiota. Therefore, the susceptibility of H. pylori to antibiotics is 
independent of coexisting bacterial flora. A review of H. pylori susceptibility to antibiot-
ics in untreated and previous treated patients will be given including meta-analyses of 
H. pylori susceptibility to metronidazole (MTZ), clarithromycin, and levofloxacin. These 
data indicate that these antibiotics become more doubtful to use for primary therapy and 
should be banned for secondary therapy without susceptibility testing.
Keywords: gastric microbiota, H. pylori, histology, susceptibility testing, resistant rates
1. Introduction
Microbiota and microbiome are not always clearly defined or distinguished. The human micro-
biota comprises the population of microbial species that live on or in the human body. This is the 
resident flora of the body and does not include the transient flora (sampling contamination, etc.). 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
The microbiome is constituted by all the genes inside these microbial cells and is thus restricted 
to detection by molecular methods (sequencing, polymerase chain reactions [PCR]) [1].
By molecular methods, bacteria are usually identified to family and genera level [2]. Bacterial 
families and genera may include species and types of bacteria that may have completely 
opposite actions in the human body [3]. It is, therefore, doubtful if molecular methods alone 
are sensitive enough to predict the effect of the composition of microbiota. The limited origi-
nal literature on gastric microbiota has mainly focused on gastric cancer and contains conflict-
ing results [4–7]. There are many difficulties in investigating the gastric microbiota. One thing 
many authors are not aware of is the difficulty of getting samples without contaminating 
bacterial flora (Figure 1) [8]. In animal models, the whole stomach can be removed, and con-
tamination of the stomach can be avoided, but in most animal species, physiology, acidity, 
etc. of the stomach are very different from the human stomach. Samples from the human 
stomach are usually taken as biopsies during gastroscopy. Even though the endoscope and 
the forceps are sterilized or decontaminated, it will be contaminated with oral bacterial flora 
during gastroscopy and thereby will the samples be contaminated by oral flora mainly of the 
phyla Firmicutes [8, 9].
Bacterial resistance to antibiotics can occur either if the bacteria obtain plasmids contain-
ing resistance genes from other bacteria in the microbiota (conjugation); they can take 
Figure 1. Schematic illustration of the gastric mucosa with the main cell types of oxyntic and pyloric glands in the gastric 
epithelium. Gastric stem cells reside in the isthmus zone of the gland and differentiate into precursors of the different cell 
lineages, which migrate either apically toward the gastric lumen or downwards to the base. The superficial epithelium 
and the gastric glands are covered by a viscous mucus layer mainly composed of MUC5AC, secreted by the SMCs, and 
MUC6, secreted mainly by MNCs and antral gland cells. The mucus layer consists of an inner layer, which is firmly 
attached to the epithelium, and an outer loose layer. The gastric pathogen Helicobacter pylori has been shown to use the 
transmucus pH gradient between the acidic gastric lumen and the near-neutral epithelial surface for spatial orientation 
to reach its niche at the juxtamucosal epithelium. The precise location of non–H. pylori microbiota is still hypothetical. [8].
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up free DNA with resistance genes from the environment (transcription) or DNA can 
be transferred by bacteriophages (transduction). Furthermore, mutations can occur in 
the bacterial genome which may result in resistance if the mutation occurs in the part 
of the genome that codes for a structure on which the antibiotics act; this action may 
be interfered, and the bacteria becomes resistant to the antibiotic [10–12]. The conjuga-
tion of plasmids increases with the number of different bacteria in the microbiota and 
depends on a close contact between the bacteria. Uptake of free DNA does not demand 
a direct contact with other bacteria, but bacteria should probably be present in the close 
environment [3]. Mutations occur in all bacteria with a certain time because of natural 
replication errors [12]. Some bacteria mutate more often than others; but because of the 
short generation time for bacteria, each bacterial clone will have several mutations. If the 
mutation occurs in a part of the genome, which is target for the antibiotics, resistance to 
the antibiotic may occur.
2. Study on gastric microbiota
In a previous unpublished study that included 411 biopsies from patients undergoing upper 
gastrointestinal endoscopy were investigated both by microaerobic culture and by histology 
(Table 1). From 249 (60%) biopsies other bacteria than H. pylori were cultured. These bacteria 
were oral flora, that is, Streptococcus spp., Staphylococcus spp., Corynebacterium spp., Neisseria 
spp., etc., which may indicate contamination of both the endoscope and the biopsies during 
the procedure. In histological sections, very few bacteria except H. pylori were seen in 20 (5%) 
of the biopsies. In all cases, the bacteria were located superficial to the mucus layer and not 
in relation to the epithelial cells and H. pylori, which confirm that it is contamination from 
the oral cavity. The discrepancy in the number of biopsies with other bacteria than H. pylori 
between culture and histology may be because very few bacteria (less than 5 colonies) are 
cultured and the preparation of histological sections may remove much of the mucin and the 
contaminating bacteria. H. pylori was found alone without contamination in 60 biopsies by 
culture and in 83 biopsies by histology which indicate that H. pylori is a true gastric micro-
biota (Figure 2).
All known mechanisms for H. pylori resistance to all antibiotics are point mutations located 
on the chromosome (Table 2), indicating no uptake of plasmids or free DNA, which support 
that H. pylori is the only bacteria in the true gastric microbiota and everything else is transient 
contaminating flora [13].
No. of biopsies Culture Histology
H. pylori Other bacteria H. pylori Other bacteria
411 106 249 83 20
Table 1. Comparison of culture and histological finding of H. pylori and other bacteria (oral flora) in gastric biopsies.
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3. Diagnosis of H. pylori
The detection of H. pylori can be done by invasive and noninvasive methods. The invasive 
methods require a biopsy, whereas the noninvasive methods are gentler for the patient.
Culture of H. pylori may be difficult and the sensitivity may be rather low (50–85%) [14]. The 
sensitivity of the culture depends on transport time to the lab and the culture method used 
[15]. Different agar plates or incubation time can also give different results on the same biopsy. 
Two biopsies from the antrum and two biopsies from the fundus are preferred when making 
a culture as H. pylori is unevenly distributed in the stomach. Culture is the only method by 
which it is possible to make a full susceptibility test.
Figure 2. Imprint cytology showing the presence of H. pylori (Giemsa stain, ×400) Rahbar [84].
Resistance to Mutation
Amoxicillin PBP1
Clarithromycin InfB
rp1V
A2142C
A2142G
A2143G
Metronidazole rdxA
frxA
fdxB
Fluoroquinolones gyrA
gyrB
Tetracycline AGA925-967TTC
Rifampicin RNA polymerase subunit beta/beta
Table 2. Examples of mutations in H. pylori causing resistance to antibiotics.
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Histology is an invasive method which requires a least one antral biopsy and preferably two 
antral and two corpus biopsies. The biopsy is stained with hematoxylin and eosin, Giemsa, or 
silver staining. H. pylori is identified by the color, shape, and close relation to the mucosa and can 
be confirmed by immunohistochemistry using H. pylori–specific antibodies. The histology has 
shown to have a sensitivity at the same level as culture but is influenced by the size of the biopsy 
[14]. The number of biopsies and the location in the stomach also modify the sensitivity. The 
specificity of histology is lower than the specificity of the culture as histology cannot distinguish 
H. pylori from non–pylori Helicobacter species. The detection rates in cultures and histology varies 
with varying expertise of examiners. If the patient is taking proton pump inhibitor (PPI), bismuth, 
or antibiotics prior to gastroscopy, it might change the shape of H. pylori from curved rod to a coc-
coid form. This form is undetectable in the routine microscopy technique and requires fluorescent 
in situ hybridization, immunohistochemistry with specific antibodies to H. pylori, or confirmation 
by the 16s rRNA and 23rRAN sequencing, which are irrespective of the shape of the bacteria [16].
H. pylori urease breaks down urea to ammonia and carbon dioxide. This feature is used in the 
diagnostic methods “rapid urease test” (RUT) and “urea breath test” (UBT). RUT is an inva-
sive method that preferably needs two biopsies. If the biopsy contains H. pylori, the release 
of ammonia increases the pH of the test medium, which is seen by a color change due to a 
pH indicator. The result of the test is fast and takes approximately ½ hour. UBT is a nonin-
vasive method where the patient ingests 13C-labeled urea. If the patient is infected with H. 
pylori, orally ingested 13C-urea is broken down to 13C-labeled carbon dioxide, which is then 
exhaled. The sensitivity of the two tests is 75–85% for RUT and >95% for UBT. Likewise, the 
UBT has a higher specificity (<95%) when compared to RUT (85–95%). For both RUT and 
UBT, PPI and antibiotics can give false negative results. Furthermore, coccoid forms of H. 
pylori would not produce urease and would therefore give a false negative result [17].
Stool antigen test is another noninvasive method. It was first successfully described in 1997 
using polyclonal antibodies [18]. Today monoclonal antibodies are used, and the sensitivity 
and the specificity are at the same levels as for UBT, but are preferred in special patients like 
children and patients with bleeding ulcers. This test can be done within ½ hour and is good 
for screening a patient for an infection with H. pylori. Despite this, antigen excretion may vary 
over time, and antigens may degrade while passing through the intestines, which may lead 
to false negative results.
The humoral antibody response to H. pylori can be measured by either serum IgG antibodies 
to H. pylori, which shows an ongoing or a previous infection, or by serum IgM antibodies, 
which shows an ongoing acute infection. H. pylori IgG antibodies can be detected in sputum 
or urine but have a much lover sensitivity and specificity than serum antibodies. Antibodies 
to H. pylori in serum can be tested by ELISA or “near patient test (NPT).” NPT uses immune-
chromatography or passive agglutination. A 2013 study compared the NPT and the ELISA 
test. The study showed that the NPT never reach 90% in sensitivity, and the frequency of 
false negatives and false positives were high [19]. Several tested ELISA kits showed a high 
specificity and sensitivity above 90%. However, the serological kits may differ considerably 
depending on the antigens that are included in the kit as antibodies to low-molecular-weight 
antigens (outer membrane antigens) decline significantly within 3 months, whereas antibod-
ies to high-molecular-weight antigens (CagA, VacA, etc.) may stay potent for years [20]. CagA 
antibodies remain stable for a long period of time and can probably be useful for the detection 
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of H. pylori infections in patients with gastric cancer when other tests are negative [21]. Due to 
local strain distribution of H. pylori, the serology kits should be made by using local H. pylori 
strains, and the kits should be locally validated [21].
Gastrin and pepsinogen are compounds produced in the stomach that depend on the changes 
in the gastric mucosa, and the serum levels of pepsinogens are a marker of atrophic gastritis 
[22]. This can be combined with the H. pylori antibody test to predict the risk of developing 
gastric cancer.
Molecular methods have been of increasing interest in the field of microbiology and for detec-
tion of H. pylori. Polymerase chain reaction (PCR) seems to be more sensitive than any other 
method to detect H. pylori [23]. The main problem is that the method does not distinguish 
between live bacteria and DNA from dead bacteria. Real-time PCR (RT-PCR), which is a fast 
and quantitative PCR, seems to be more sensitive than classical PCR [24]. By sequencing the 
16S RNA or 23S RNA region, it is possible to detect Helicobacter species and susceptibility to 
clarithromycin and tetracycline [25–27]. However, it is a more expensive and time-consuming 
method. A commercial kit has combined detection of H. pylori and susceptibility to clarithro-
mycin in a classical PCR. However, culture is still needed for a full susceptibility testing. 
There are so many point mutations causing resistance to antibiotics in H. pylori that a full 
susceptibility analysis can only be detected by whole genome sequencing [28].
4. H. pylori susceptibility to antibiotics
During the last decade, an increased number of H. pylori have become resistant to antibiotics, 
especially to clarithromycin and levofloxacin [29]. The resistance rates to metronidazole have 
always been more than 15% worldwide, but the increasing resistance rates to clarithromycin 
and levofloxacin in some areas have become higher than 10–15%. Thus, these antibiotics are 
not recommended for first-line therapy of H. pylori without prior susceptibility testing [21]. It 
is common to treat H. pylori infections without prior susceptibility testing, and different stud-
ies show a much lower resistance rate to clarithromycin in H. pylori from untreated patients 
than in H. pylori from previously treated patients [30–32]. It is therefore of the greatest impor-
tance to make susceptibility testing after the first treatment failure.
The susceptibility testing of H. pylori can be done by various methods. The most common are 
dilution methods, disk diffusion, and E-test.
The dilution method is regarded to be the golden standard for susceptibility testing. A two-
fold dilution row of the test antibiotic is made. A standard number of bacteria (McFarland 3) 
are added to each tube with antibiotics. The bacterial growth is inhibited by high concentra-
tions of antibiotics. The first tube with bacterial growth is called the minimal inhibitory con-
centration (MIC). H. pylori should be grown for 48–72 hours under microaerobic conditions. It 
may be difficult to find a suitable media in which H. pylori grows fast enough, and the slight-
est contamination will grow faster than H. pylori and thereby spoil the susceptibility testing.
The disk diffusion test requires a small tablet of an antibiotic. The tablet is placed on the agar 
plate and is incubated for 3 days. After 3 days, there will be a zone around the tablet with no 
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growth of H. pylori. This is the inhibition zone, and the diameter of the zone can be translated 
to an MIC value, which shows whether or not the bacteria are resistant to the antibiotic. To 
make the susceptibility testing of H. pylori, a McFarland 3.0 dilution of H. pylori and Mueller-
Hinton agar plates with 10% blood or chocolate ager plates should be used and incubated in 
microaerobic conditions at 37°C.
The E-test is a stripe with a concentration gradient of an antibiotic. The stripe is placed on the 
agar plate and is incubated for 3 days. After 3 days, there will be a droplet shape around the 
stripe with no growth of H. pylori (Figure 3). That concentration where H. pylori grows close to 
stripe is the MIC value [33].
5. Treatment of H. pylori infection
H. pylori infections are usually treated with a combination of antibiotics and nonantibiotics 
(proton pump inhibitor [PPI] or bismuth salts). Usually, a combination of two or three anti-
biotics is used, as the effect of monotherapy has been found insufficient. The most commonly 
used antibiotics are amoxicillin, clarithromycin, metronidazole, fluoroquinolones, tetracy-
cline, and rifampicin (Table 3).
H. pylori is found in very different environments such as the gastric lumen with a relatively 
low pH, in between the epithelial cells and on the basement membrane with a neutral pH but 
protected as intracellular microorganisms. When choosing antibiotics, it is important to select 
antibiotic to which H. pylori is sensitive and is active in all the environmental niches where H. 
pylori occurs. It is also important to look at the duration of the efficacy of antibiotics to keep 
stable levels above the minimal inhibitory concentrations.
PPI in standard doses do not have antibacterial effect on H. pylori, but 5–10 times higher 
doses have a direct effect on H. pylori. Bismuth salts binds to the surface of H. pylori but have 
Figure 3. Reading guide for E tests. (A) Colonies of a metronidazole-resistant subpopulation in the ellipse minimum 
inhibitory concentration (MIC) >32; (B) trailing of microcolonies at the end point MIC 0.5 μg/ml. Warburton-Timms and 
McNulty [85].
Gastric Microbiota and Resistance to Antibiotics
http://dx.doi.org/10.5772/intechopen.80662
97
a relatively little antibacterial effect. However, bismuth salts affect the respiratory chain at the 
same points as metronidazole and thereby reverts metronidazole resistance in H. pylori and 
thus becomes sensitive to metronidazole.
6. Prevalence of H. pylori resistance to antibiotics
When analyzing different studies around the world, the primary resistance rate for H. pylori 
varies. The highest rate of primary metronidazole (MTZ) resistance is found in Africa (52%) 
followed by South America (49%) and Asia (43%). The lowest resistance rate is found in 
Europe (35%). The highest primary resistance rates for clarithromycin and levofloxacin are 
found in South America (20 and 27%) while the lowest rates are found in Europe (12 and 10%) 
[30–32, 34–67]. There is a significantly (p < 0.001) higher risk of primary metronidazole and 
levofloxacin resistance in Asian when compared to Europe.
The high rate of metronidazole resistance seen in developing countries may be due to the 
high use of metronidazole for treatment of parasites and gynecological infections [62, 68]. 
It is therefore likely that the patients who are treated for H. pylori with metronidazole for 
the first time are resistant for this treatment. It is recommended to use bismuth therapy 
together with metronidazole in the first-line treatment in areas with high metronidazole 
resistance [21].
The high resistance rates for clarithromycin and levofloxacin in South America, Africa, and 
Asia can be due to the use of huge amounts of antibiotics in general [69]. Typically, the diag-
nostics are not precise, and the patients are treated with more a broad spectrum of antibiotics 
for a longer period. This can lead to a faster development of resistance in H. pylori [70].
Group Preparation
Antibiotics Amoxicillin
Clarithromycin
Metronidazole
Tetracycline
Levofloxacin
Ciprofloxacin
Rifampicin
Nonantibiotics PPI
Bismuth nitrate
Bismuth citrate
Bismuth subsalicylate
H
2
 blocker
Table 3. Commonly used antibiotics and nonantibiotics for treatment of H. pylori infections.
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A large multinational study tested H. pylori resistance in 18 European countries [29]. All 18 
countries used E-test for the susceptibility testing and only tested patients who had never 
been treated for H. pylori before. In total, 2204 people were included in the study, and the 
resistance rate for adults were 18% for clarithromycin, 14% for levofloxacin, and 35% for met-
ronidazole. They found a significant association between the use of only long-acting macro-
lides and clarithromycin resistance. The levofloxacin resistance was significantly associated 
with the use of quinolone.
The prevalence of H. pylori resistance to antibiotics was tested in Denmark in 1997, 1998–2004, 
and 2013 [71–73]. Throughout the years, the resistance for clarithromycin has increased from 
0% in 1997 to 53% in 2013, and likewise, the resistance for metronidazole increased from 20 to 
74% [12–14]. None of the studies mention whether or not the patients have had H. pylori eradi-
cation therapy prior to testing or not, which might explain the huge increase in resistance.
6.1. Effect of antibiotic treatment on H. pylori resistance rates
International guidelines recommend first line of treatment of H. pylori infections with 10 days 
of triple therapy (PPI, clarithromycin, and metronidazole or amoxicillin). If this fails, a treat-
ment with four types of medicine (PPI, bismuth subsalicylate, tetracycline, and metronidazole) 
for 2 weeks is recommended. After treatment failure for the second time, it is recommended to 
perform a gastroscopy and susceptibility testing for H. pylori [21].
The primary and secondary resistance rate for H. pylori has only been described in eight stud-
ies [30, 32, 40, 43, 58, 65, 66, 74]. By using “Review Manager 5.3,” it is possible to compare the 
studies via Forest plots. The meta-analyses show that the secondary resistance is significantly 
higher (p < 0.001) than the primary.
The meta-analysis shows a high increasing resistance rate for all three antibiotics when the 
patient had been treated for H. pylori previously. The high and increasing resistance rates 
to metronidazole, clarithromycin, and levofloxacin make it uncertain that these antibiotics 
should be recommended as the first-line therapy of H. pylori infections without prior endos-
copy and susceptibility testing (Figure 4A–C).
6.2. Vaccine
Another way to overcome H. pylori infections is with a vaccine. In the past couple of years, 
many studies have investigated developing an effective and safe vaccine. The development 
of an effective vaccine is complicated by the noninvasive nature of H. pylori. It stays in the 
lumen of the stomach and does not cross the epithelium. Therefore, the vaccine should 
affect T helper memory cells, which are required to stay in the lumen during a H. pylori 
infection [75].
Appropriate bacterial antigens, safe and effective adjuvants, and a route of delivery are required 
for developing a vaccine. For the bacterial antigen, most studies use urease, but other antigens are 
investigated for example Cag L. The CagL is a protein essential for the pathogenesis of H. pylori. It 
binds to integrins in the mucosa and triggers the release of the carcinogen CagA to the host cells 
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through the type IV secretin system. CagL also introduces an IL-8 response, which causes inflam-
mation [76]. The use of CagL in a subunit vaccine was investigated by Choudhari et al. in 2013 
[75]. The study showed that CagL was stable in pH 4–6 and that sucrose enhances the stability.
The use of heat shock proteins in a vaccine introduced protective immunity without requir-
ing the addition of an adjuvant. The protection, however, is not optimal because sterilizing 
immunity is not obtained, which is shown in a study from 2014 [77].
A derivate of the cholera toxin (CTA1-DD) and safe nontoxic mutants of Escherichia coli heat labile 
toxin (dm2T) have also been tested as potential adjuvants. CTA1-DD enhances the Th1 and Th17 
immunity and reduces the bacterial colonization by three- to eight-fold [78]. The use of dm2T 
was equally as effective as the gold standard H. pylori vaccine containing cholera toxin [79].
Figure 4. Meta-analysis for MTZ (A), CLR (B), and LEV (C). For all three antibiotics, there is a higher odds ratio for 
resistance if the patient is previously treated for infection with H. pylori.
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The routes of delivery that have been tested are sublingual, intranasal, respiratory, and oral 
[79]. A study on humans from China (2015) tested a vaccine based on a urease B subunit and 
heat-labile enterotoxin B subunit (gene derived from E. coli H44815) [80]. The vaccine was 
taken orally three times (day 0, 14, and 28). This study showed a vaccine efficacy of 71.8% in 
the first year, 55% in in the second year, and 55.8% in the third year after vaccinations. Even 
though these findings are excellent, a 100% effective vaccine is still not developed. More stud-
ies and longer time follow-ups are needed before a fully effective vaccine is on the market. If a 
fully effective vaccine is made, it would be the best heath measure against H. pylori infections 
and gastric cancer.
7. Discussion
The human gastric microbiota may be difficult to estimate since samples for microbiome inves-
tigations often are contaminated with oral bacterial flora during gastroscopy. And the studies 
in these fields do not make any attempt to remove the oral contamination prior to sequencing. 
Histological examination of biopsies reveals H. pylori as the only bacteria in close relation to the 
epithelial cells in the gastric mucosa. When H. pylori is seen in stomach samples, there is always 
a strong humoral and cellular immune response to H. pylori and it thereby fulfills the criteria for 
a true infection but also a colonization. This has not been shown for any other bacteria.
Thus, in noncancer patients, H. pylori seems to be the gastric microbiota. In patients with 
gastric cancer, there may be a different situation as the mucosa is disintegrated and an over-
growth of intestinal bacteria is common. However, it remains to be shown that the intestinal 
bacteria adhere to the gastric mucosa and cause a local immune response. It is, therefore, 
believed that H. pylori is still the most important gastric pathogen.
An increasing resistance to antibiotics in H. pylori has been seen worldwide especially to metro-
nidazole, clarithromycin, and levofloxacin. This is a worrying development as it may interfere 
with our recommendations for primary treatment of H. pylori without susceptibility testing. 
It is a question how fast the resistance occurs. Should susceptibility testing be done after first 
treatment failure or can it wait until the second treatment failure as recommended? At least 
the resistance rates are much higher in previously treated patients than in untreated patients.
Due to the high resistant rates, it is necessary to perform a susceptibility test before starting the 
treatment. The advantages would be a better and maybe quicker eradication of the H. pylori 
infection. Disadvantages of early susceptibility testing are the cost and time of the analyses. 
Biopsies are an invasive method and may often be painful for the patient. Furthermore, it takes 
up to 14 days before a full susceptibility test is completed, so the real treatment starts approxi-
mately 2 weeks after the doctor confirms the presence of H. pylori. By this time, the patient 
could have been done with the first line of treatment. In the short perspective, a quick suscepti-
bility test would be very time consuming, but in the long perspective, it might save the patient 
from several treatments and prevent the relapse of the H. pylori infection. But it also gives a 
better overview on how quickly H. pylori develops resistance to the recommended treatment.
When detecting H. pylori, the best would be a quick a method that was as quick as PCR but 
also made it possible to have a full susceptibility test incorporated. New primers for detecting 
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antibiotic resistance are in progress, but the problem is that there are many different muta-
tions leading to the same resistance profile. H. pylori only develops antibiotic resistance by 
mutation in the genome. For MTZ, mutations in at least nine different genes are known to 
contribute to MTZ resistance [13]. If the detecting of MTZ resistance should be made by PCR, 
it would be necessary to perform the PCR with many different primers all looking for one 
specific mutation. In theory, this would be the most sensitive way to find MTZ resistance, but 
in practice, it would be almost impossible, take a lot of time, and would be expensive.
Due to the enormous amount of mutations leading to antibiotic resistant, the culture and 
susceptibility testing done by E-test is still the best and most economical way.
The increasing resistant rates to the most commonly used antibiotics raises the question of 
whether other antibiotics or combinations of antibiotic and nonantibiotic should be used for 
primary treatment of H. pylori infections without susceptibility testing. Bismuth compounds 
in standard doses, proton pump inhibitors, and acid suppressing compounds in high doses 
may convert the MTZ resistance [81]. This makes MTZ useful in combination with these 
compounds, especially the bismuth compounds, which have been shown in clinical studies 
[21]. Nonantibiotics such as neuroleptics and other compounds acting on the central nerves 
system have anti–H. pylori effect in vitro [82] and compounds without effect on the central 
nervous system may be candidates for alternative treatment. Herbs like broccoli and green 
tee have some effect on H. pylori and may in combination with antibiotics and nonantibiotics 
be candidates for treatment in the future [83].
8. Conclusion
H. pylori is the most important gastric pathogen and may constitute the true gastric microbiota. 
It is, therefore, important to follow the development of resistance in H. pylori to antibiotics. 
With the increased resistance of H. pylori to metronidazole, clarithromycin, and levofloxacin, 
it may be doubtful if these antibiotics can be recommended as primary treatment without 
susceptibility testing.
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